Global Certolizumab Pegol Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Certolizumab Pegol Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Certolizumab pegol (CDP870, tradename Cimzia) is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Certolizumab Pegol report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Certolizumab Pegol market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Crohn’s disease and Active rheumatoid arthritis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Certolizumab Pegol industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Certolizumab Pegol key companies include UCB. etc. UCB, , are top 3 players and held % share in total in 2022.
Certolizumab Pegol can be divided into Single-dose vial and Single-dose prefilled syringe, etc. Single-dose vial is the mainstream product in the market, accounting for % share globally in 2022.
Certolizumab Pegol is widely used in various fields, such as Crohn’s disease, Active rheumatoid arthritis and Active psoriatic arthritis,, etc. Crohn’s disease provides greatest supports to the Certolizumab Pegol industry development. In 2022, global % share of Certolizumab Pegol went into Crohn’s disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Certolizumab Pegol market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
UCB
Segment by Type
Single-dose vial
Single-dose prefilled syringe
Crohn’s disease
Active rheumatoid arthritis
Active psoriatic arthritis
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Certolizumab Pegol market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Certolizumab Pegol introduction, etc. Certolizumab Pegol Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Certolizumab Pegol market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Certolizumab Pegol report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Certolizumab Pegol market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Crohn’s disease and Active rheumatoid arthritis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Certolizumab Pegol industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Certolizumab Pegol key companies include UCB. etc. UCB, , are top 3 players and held % share in total in 2022.
Certolizumab Pegol can be divided into Single-dose vial and Single-dose prefilled syringe, etc. Single-dose vial is the mainstream product in the market, accounting for % share globally in 2022.
Certolizumab Pegol is widely used in various fields, such as Crohn’s disease, Active rheumatoid arthritis and Active psoriatic arthritis,, etc. Crohn’s disease provides greatest supports to the Certolizumab Pegol industry development. In 2022, global % share of Certolizumab Pegol went into Crohn’s disease filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Certolizumab Pegol market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
UCB
Segment by Type
Single-dose vial
Single-dose prefilled syringe
Segment by Application
Crohn’s disease
Active rheumatoid arthritis
Active psoriatic arthritis
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Certolizumab Pegol market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Certolizumab Pegol introduction, etc. Certolizumab Pegol Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Certolizumab Pegol market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices